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The Clinical and Serological Effect of a Gluten-Free Diet in Border
Terriers with Epileptoid Cramping Syndrome
M. Lowrie, O.A. Garden, M. Hadjivassiliou, R.J. Harvey, D.S. Sanders, R. Powell, and L. Garosi
Background: Canine epileptoid cramping syndrome (CECS) is a paroxysmal movement disorder of Border Terriers (BTs).
These dogs might respond to a gluten-free diet.
Objectives: The objective of this study was to examine the clinical and serological effect of a gluten-free diet in BTs with
CECS.
Animals: Six client-owned BTs with clinically confirmed CECS.
Methods: Dogs were prospectively recruited that had at least a 6-month history of CECS based on the observed phe-
nomenology (using video) and had exhibited at least 2 separate episodes on different days. Dogs were tested for anti-transglu-
taminase 2 (TG2 IgA) and anti-gliadin (AGA IgG) antibodies in the serum at presentation, and 3, 6, and 9 months after the
introduction of a gluten-free diet. Duodenal biopsies were performed in 1 dog.
Results: Serum TG2 IgA titers were increased in 6/6 BTs (P = .006) and AGA IgG titers were increased in 5/6 BTs at
presentation compared to those of controls (P = .018). After 9 months, there was clinical and serological improvement in all
BTs with CECS strictly adhering to a gluten-free diet (5/5). One dog had persistently increased antibody titers. This dog scav-
enged horse manure. On the strict introduction of a gluten-free diet this dog also had an improved clinical and serological
response. The diet-associated improvement was reversible in 2 dogs on completion of the study, both of which suffered a
relapse of CECS on the re-introduction of gluten.
Conclusions: Canine epileptoid cramping syndrome in BTs is a gluten-sensitive movement disorder triggered and perpetu-
ated by gluten and thus responsive to a gluten-free diet.
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Canine epileptoid cramping syndrome (CECS) is aparoxysmal movement disorder of Border Terriers
(BTs) that is analogous to paroxysmal nonkinesigenic
dyskinesias (PNKD) in humans.1,2 Canine epileptoid
cramping syndrome is characterized by attacks of invol-
untary movements (dystonia, chorea, ballism, tremor,
and athetosis) occurring at rest with no loss of con-
sciousness.2 Episodes occur in dogs as young as
6 weeks, but can develop up to 7 years of age.2 Border
Terriers experience paroxysms, often in response to
stress or excitement, affecting the extremities, head and
neck, often associated with borborygmi.2 Although mild
episodes consist of tightening of muscles in the extremi-
ties, followed by choreoathetosis and involuntary
postures (dystonia), involuntary movements might be
severe and prevent functional use of the limbs.2 Epi-
sodes last from minutes to hours and might occur as
frequently as several times each day, or be interspersed
by months or years.2 The cause of CECS is unknown,
and treatment is often unsatisfactory with no medica-
tion being reported to have a beneficial effect.2 Neuro-
logical examination between episodes is normal and
cross-sectional imaging of the brain and spinal fluid
analysis did not detect abnormalities. A clinical diagno-
sis relies on the exclusion of other causes for paroxys-
mal episodes by recognition of the features of CECS
during an episode.2 Video footage is frequently invalu-
able in the assessment of CECS. Anecdotal reports
among owners and breeders suggest that the replace-
ment of a gluten-free diet might reduce the frequency
and severity of CECS episodes. This view was further
supported by the finding that over 50% of BTs with
CECS responded to a gluten-free or hypoallergenic diet
according to their owners.2
Celiac disease (CD) is an immune-mediated enteropa-
thy triggered in genetically susceptible individuals by
the ingestion of gluten.3 However, this term should
be reserved for those patients with gluten-sensitive
enteropathy; characterized by an abnormal duodenal
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biopsy of an increased density of intraepithelial lympho-
cytes to villous atrophy, in the presence of transglutami-
nase-2 antibodies (autoantibodies against an enzyme
that breaks down gliadin) in serum.3 The more recently
coined term, nonceliac gluten sensitivity (NCGS), com-
prises a spectrum of conditions in humans, all of which
are characterized by an immune response to the inges-
tion of gluten, but with diverse manifestations4 such as
an enteropathy5 (distinct to CD), dermatopathy (der-
matitis herpetiformis)6; and neurological disorders such
as gluten ataxia.7 In patients with neurological manifes-
tations of NCGS, antibodies against gliadin (the protein
responsible for gluten sensitivity) are the best diagnostic
markers.8,9
Our first objective was to establish any therapeutic
effects of a gluten-free diet in BTs with CECS. Our sec-
ond objective was to provide serological evidence that
an association exists between CECS and gluten sensitiv-
ity.
Materials and Methods
Animals
Serum samples were collected from 6 BTs with a clinical diag-
nosis of CECS presented to Davies Veterinary Specialists between
March 2012 and July 2014. Owners were asked to sign an
informed consent document before inclusion of their dog in the
study.
Criteria for Case Selection
A video was obtained of a typical episode from each dog and
was evaluated by 2 of the authors (ML, LSG). Based on the
observed phenomenology in conjunction with the medical history,
a diagnosis of CECS was made. This is in accordance with the
diagnosis of CECS in a previous study.2
Information obtained and recorded from the medical records of
CECS dogs consisted of signalment (age and sex); history (first
onset, progression, frequency and duration of episodes); signs sug-
gestive of gastrointestinal disease (specifically vomiting, diarrhea,
persistent borborygmi); and concurrent medical conditions. Dogs
with a history of receiving a gluten-free diet before accession were
excluded from the study. All dogs had to have at least a 6-month
history of CECS and have exhibited at least 2 separate episodes
on different days.
Each dog was subjected to a complete general physical and neu-
rological examination by a veterinary neurologist (ML, LSG). A
minimum database for each dog consisted of the following: com-
plete blood cell count (CBC), serum biochemistry profile, routine
urinalysis, and dynamic bile acid concentrations. In selected dogs,
additional testing was performed including magnetic resonance
imaging of the brain (using a 0.4T magneta), cerebrospinal fluid
analysis (collected from the cerebellomedullary cistern) by cytolog-
ical review and total protein assay, and gastroduodenoscopy with
the collection of endoscopic biopsy samples from the stomach and
descending duodenum attained with flexible endoscopic biopsy for-
ceps.
Dietary Trial
All dogs were then fed an exclusively gluten-free diet.b
Participants were instructed to switch their dog to the new diet
progressively, over 7 days, by gradually increasing the proportion
of new diet fed. Instructions also were given about ensuring that
the chosen diet was fed exclusively by avoiding consumption of
treats or table scraps, preventing outdoor scavenging and avoid-
ing access to food of other dogs in the household by feeding
individual dogs separately and lifting up food bowls when not in
use. No other medication was given throughout the trial. During
this time, owners were asked to keep a diary and record any epi-
sodes.
Follow-Up
A re-examination was scheduled 3, 6, and 9 months after start-
ing the gluten-free diet, in which a full general physical and neuro-
logical examination was performed alongside a CBC and serum
biochemistry profile.
Sample Collection
A serum sample was collected at presentation and at 3, 6, and
9 months in all dogs. Serum samples were also collected from BTs
with no history of CECS having medical investigations for condi-
tions unrelated to neurological or gastrointestinal disease to serve
as controls. All serum samples were stored at 80°C until assayed.
Serology
All serum samples were tested for serologic evidence of antica-
nine transglutaminase-2-IgA (TG2 IgA) autoantibodies and antica-
nine gliadin-IgG (AGA IgG) antibodies utilizing a commercial
laboratory,c These markers were selected owing to their utility as
diagnostic markers of gluten sensitivity in humans.3,8,9
For detection of antibodies against canine tissue, transglutami-
nase-2, the antigen was coated onto a microtiter plate. The plate
surface was blocked with bovine serum albumin prior to use with
canine sera and control samples. Bound antibodies against canine
TG2 were detected by incubation with peroxidase-conjugated sec-
ondary antibody against canine IgA. In the last step, the peroxi-
dase converts a substrate (tetramethylbenzidine) into a blue
product, which upon addition of the stop solution (0.5 M H2SO4)
turns yellow. Negative control values were recorded using a buffer
and conjugate.
Regarding IgG antigliadin antibodies, the gliadin-coated micro-
titer plate from the ELISA for the determination of antibodies
(IgG) against gliadin from Steffens Biotechnische Analysen was
used.d Detection of bound antibodies against gliadin was obtained
by incubation with peroxidase-conjugated secondary antibody
against canine IgG1. Negative control values were recorded using
a buffer and conjugate.
Statistical Analysis
Analyses of correlations between the CECS dogs and the
control group were performed using the Mann–Whitney test. A
P-value of <.05 was considered to be significant. All statistical tests
were performed using a commercial software package.e
Results
Animals
A total of 6 BTs were included in this study. The
mean age of the BTs at episode onset was 2.6 years
(median 3 years; range, 1–4 years). Three BTs were
female (50%; 2/3 neutered) and 3 were male (50%; 3/3
neutered).
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Dyskinesia Episodes
Border Terriers had shown the clinical signs for a
mean of 1.4 years at presentation (median 1.5 years;
range, 6 months–2 years). Mean episode frequency was
1 per month (median 1 episode every 2 months; range,
1 episode every 3 months up to 1 episode per week).
The mean duration of an episode was 15 minutes (me-
dian 5 minutes; range, 2–60 minutes).
Concurrent Clinical Signs
In 2/6 BTs, owners reported signs suggestive of gas-
trointestinal disease. In 1 dog this included borborygmi
and occasional vomiting. In the other dog, this was
reported as frequent soft stools.
Investigations
Results of general physical examination, neurological
examination, CBC, serum biochemistry profile, and
dynamic bile acid concentrations did not detect any
abnormalities (n = 6). In 4 dogs, an MRI scan was per-
formed with spinal fluid analysis, yielding normal
results. In 1 dog (dog 1) with signs suggestive of gas-
trointestinal disease (borborygmi and occasional vomit-
ing) gastroduodenoscopy with collection of endoscopic
biopsies of the stomach and duodenum did not reveal
abnormalities.
Response
Three BTs (dogs 1, 4, and 5) had no further episodes
of CECS after commencing the dietary trial. Two BTs
(dogs 2 and 3) had 1 and 2 episodes, respectively,
within 4 weeks of starting the trial, but have subse-
quently experienced no further episodes. The final dog
(dog 6) continued to have episodes throughout the
study period.
Antibody Titers
Serum samples were available from all 6 dogs at pre-
sentation and in 5 control BTs. At presentation, all 6
BTs had increased values of antitransglutaminase-2
antibodies (TG2 IgA; median 0.808; range 0.714–1.154)
compared to the control group (median 0.216; range
0.129–0.285; P = .006). Buffer and conjugate negative
control values were 0.219 and 0.213 respectively. In 5
dogs, serological evidence of elimination of TG2 IgA
was observed, correlating with clinical remission of
CECS episodes in these dogs (Fig 1). All 6 owners
claimed to have adhered to the gluten-free diet for their
dogs, but one of these BTs (dog 6) had persistently high
TG2 IgA and continued to experience episodes of
CECS. On further questioning of the owner, it became
apparent that this dog had been scavenging horse man-
ure during the study. Therefore, the owner was asked to
eliminate this from the dog’s oral intake and 3 months
after commencing the proper gluten-free diet, a serologi-
cal response was observed and no further CECS
episodes were reported. Subsequently this dog was
removed from the study because of protocol violation.
Furthermore, at the end of the trial, 2 owners unwit-
tingly re-introduced gluten-containing “treats” to their
dog’s diet. On doing so, both dogs relapsed with an epi-
sode of CECS. They duly returned to using the gluten-
free diet and have subsequently been faring well,
although autoantibodies were not measured at the time
of relapse.
Anti-gliadin antibodies (AGA IgG) were also signifi-
cantly increased (median 0.398; range 0.175–0.641) com-
pared to control dogs at presentation (median 0.121;
range 0.092–0.162; P = .018), but the scope of increase
was not such as to be of clinical importance. Buffer and
conjugate negative control values were 0.096 and 0.105,
respectively. However, titers decreased on institution of
a gluten-free diet in all 5 dogs that clinically responded
and ultimately in the sixth dog once the owner was
compliant with the gluten-free diet (Fig 2).
Discussion
These investigations support the hypothesis that
CECS is a manifestation of gluten sensitivity, making
this the first paroxysmal movement disorder in veteri-
nary medicine with a serological link to gluten.
Gluten comprises both gliadin and glutenin proteins
with evidence suggesting that the gliadin fraction
induces disease.10 Gliadin is a unique protein in that it
contains a large number of glutamine residues. Tissue
transglutaminase is an enzyme that, among its other
functions, catalyzes the deamidation of glutamine resi-
dues to glutamic acid.11 This process might result in the
creation of new epitopes that could play a pivotal role
in the immunopathogenesis of gluten sensitivity.12 At
present, a causative link between transglutaminase
activity and gluten sensitivity has not been definitely
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Fig 1. Chart demonstrating the serological response of antitrans-
glutaminase-2 IgA to a gluten-free diet in 5 dogs with canine
epileptoid cramping syndrome (dog 6 excluded due to failure to
adhere to methods). The time periods of monitoring were initial
presentation, 3, 6, and 9 months after commencement of a gluten-
free diet. Each dog is indicated with a different line.
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established though evidence supporting this hypothesis
is strong.13
In recent years, the view of CD has undergone a pro-
found revision. The first indication that gluten can
cause extra-intestinal signs came from a study that
described a gluten-dependent skin rash (known as der-
matitis herpetiformis) that could occur even without
histological evidence of intestinal involvement.6 Neuro-
logical signs occur in patients with histologically con-
firmed CD.14 Recognition of neurological
manifestations of NCGS have since increased, the most
common being gluten ataxia7 and peripheral neuropa-
thy.15 However, signs of chorea,16 stiff person syn-
drome,17 seizures,18 and a recently described clinical
entity of myoclonic ataxia19 are less common. Tentative
links of a PNKD in a 10-year-old girl responding to a
gluten-free diet were not supported by serological
assays.20
Initially, the assumption had been that neurological
signs associated with NCGS were secondary to a mal-
absorption with subsequent vitamin deficiencies in view
of the concurrent enteropathy in these patients.14 How-
ever, neurological signs emerged even in the absence of
enteropathy, suggesting an alternative etiology.21 Cur-
rent evidence suggests that neurologic manifestations
are immune-mediated. This is based on histopathologi-
cal findings from patients with gluten ataxia that
demonstrate macroscopic cerebellar atrophy visible on
MRI with diffuse infiltration of T lymphocytes within
the cerebellar white matter and perivascular cuffing with
inflammatory cells.22 Although the presence of the anti-
gliadin antibody is historically considered to be an
important hallmark of CD, lower figures for its sensitiv-
ity and specificity in comparison to TG2-IgA have led
to a diminished utility of the marker for diagnosis.3
However, the emergence of NCGS identified that AGA
IgG are more robust markers than TG2-IgA for the
extra-intestinal manifestations of gluten sensitivity.21
Given that only 40% of the patients with neurological
manifestations due to gluten sensitivity responsive to a
gluten-free diet will have an enteropathy21, it has
become standard practice to measure both markers in
people and it seems appropriate to adhere to a similar
method in dogs.
The association of gluten with CECS might give an
explanation as to why a proportion of dogs with CECS
exhibit signs of gastrointestinal disease.2 In gluten
ataxia <10% of patients will have signs of gastrointesti-
nal disease, but up to one-third will have evidence of
enteropathy on biopsy.23 One dog in the present study
with borborygmi and occasional vomiting had no histo-
logical evidence of enteritis. The owner of the second
dog with signs suggestive of gastrointestinal disease did
not consent to endoscopic examination. Further studies
are required to assess the prevalence and nature of
chronic enteropathy in BTs with CECS to determine if
these dogs have a neurological manifestation of CD or
a NCGS.
The addition of recombinant canine TG2 antigen to
the samples before testing them in the ELISA is
required to exclude non-specific effects. However, the
measurement of canine anti-TG2 antibodies has previ-
ously been performed in the cerebrospinal fluid of dogs
presenting with inflammatory meningoencephalitis in
which verification of the ELISA was performed success-
fully.24 Measurement in the serum has not previously
been undertaken.
The evidence for the existence of gluten-responsive
CECS presented in this study is the presence of anti-
gliadin and TG2 antibodies in multiple serum samples
and the clinical and serological response to a gluten-free
diet. Furthermore, the re-introduction of a gluten diet
in 2 dogs resulted in a relapse of CECS. However, a lar-
ger number of dogs will be required to ascertain the
clinical importance and utility of these observations.
Our study design might be associated with bias—for
example, owners might be more likely to default from
the diet if they see no immediate improvement in signs.
However, we emphasized to the owners that improve-
ment on the diet, if at all, was likely to be slow and to
take several months. An additional source of bias was
that 1 investigator undertook all clinical assessments
and was not blinded to the treatment state of the dogs.
Furthermore, owners might have been able to reduce
exposure to inciting causes such as excitement following
counseling by a veterinary neurologist which could, in
part, explain the reduction in the frequency of episodes
following the instigation of the diet. A double-blinded
randomized placebo-controlled trial is required to over-
come some of these limitations. Furthermore, future
studies will verify the clinical utility of these results by
the addition of canine TG2 antigen to the samples
before testing them in the ELISA, in order to exclude
nonspecific effects.
Conclusions
Serological testing for anti-transglutaminase-2 and
anti-gliadin antibodies might represent an useful
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Fig 2. Chart demonstrating the serological response of anti-glia-
din IgG to a gluten-free diet in 5 dogs with canine epileptoid
cramping syndrome (dog 6 excluded because of failure to adhere
to methods). The time periods of monitoring were initial presenta-
tion, 3, 6, and 9 months after commencement of a gluten-free diet.
Each dog is indicated with a different line.
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diagnostic tool for CECS and for monitoring dietary
compliance, especially in dogs who are nonadherent to
a gluten-free diet. Determination of gluten sensitivity
and switching to a gluten-free diet should be considered
in BTs exhibiting dyskinesia.
Footnotes
a Aperto permanent magnet, Hitachi, Tokyo, Japan
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e XLStats; Excel, Windows
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